Table 3.
Univariate analysis of prognostic factors affecting OAS and EFS rates.
| P value | 3-year EFS | P value | 3-year OAS | factor |
|---|---|---|---|---|
| 1-Age | P = 0.0005 | P = 0.0004 | ||
| 1 year (12)> | 80% | HR:0.26,95%CI; | 80% | HR:0.26,95%CI; |
| ≥1 years (41) | 28.9% | 0.12-0.55 | 16.2% | 0.12-0.55 |
| 2-Sex | P = 0.902 | P = 0.84 | ||
| Males (35) | 41.4% | HR:1.05,95%CI; | 30.9% | HR: 1.09, 95%CI; |
| Females (18) | 34.7% | 0.502-2.184 | 28.1% | 0.52 - 2.24 |
| 3-Risk group | p < 0.0001 | p < 0.0001 | ||
| Low Risk (4) | 100% | 100% | ||
| Intermediate Risk (13) | 74.6% | 74.6% | ||
| High Risk (36) | 20.7% | 6.1% | ||
| 4-Primary site | P = 0.059 | P = 0.23 | ||
| a) Adrenal glands (46) | 32.7% | HR:2.44,95%CI; | 27% | HR: 1.77, 95%CI; |
| b)Other sites (7) | 71.4% | 0.97-6.16 | 57.1% | 0.697 - 4.530 |
| 5-MYCN amplification | P = 0.0027 | P < 0.0001 | ||
| yes (11) | 8.3% | HR:4.58; 95%CI; | 0 | HR:10.64; 95%CI; |
| no (42) | 49% | 1.69 - 12.37 | 37.2% | 3.47 - 82.63 |
| 6-Local RT administration | p = 0.0078 | p = 0.032 | ||
| Yes (25) | 57.6% | HR:0.39; 95%CI; | 42.5% | HR:0.47; 95%CI; |
| No (28) | 23.4% | 0.19 - 0.78 | 19.5% | 0.24-0.94 |